Properties of Neutral Charmed Mesons in Proton--Nucleus Interactions at 70 GeV

The results of treatment of data obtained in the SERP-E-184experiment "Investigation of mechanisms of the production of charmed particles in proton-nucleus interactions at 70 GeV and their decays" by irradiating the active target of the SVD-2 facility consisting of carbon, silicon, and lead plates, are presented. After separating a signal from the two-particle decay of neutral charmed mesons and estimating the cross section for charm production at a threshold energy {\sigma}(c\v{c})=7.1 \pm 2.4(stat.) \pm 1.4(syst.) \mub/nucleon, some properties of D mesons are investigated. These include the dependence of the cross section on the target mass number (its A dependence); the behavior of the differential cross sections d{\sigma}/dpt2 and d{\sigma}/dxF; and the dependence of the parameter {\alpha} on the kinematical variables xF, pt2, and plab. The experimental results in question are compared with predictions obtained on the basis of the FRITIOF7.02 code.Comment: 9 pages, 9 figures,3 table

Observation of narrow baryon resonance decaying into pKs0pK^0_s in pA-interactions at 70GeV/c70 GeV/c with SVD-2 setup

SVD-2 experiment data have been analyzed to search for an exotic baryon state, the $\Theta^+$-baryon, in a $pK^0_s$ decay mode at $70 GeV/c$ on IHEP accelerator. The reaction $pA \to pK^0_s+X$ with a limited multiplicity was used in the analysis. The $pK^0_s$ invariant mass spectrum shows a resonant structure with $M=1526\pm3(stat.)\pm 3(syst.) MeV/c^2$ and $\Gamma < 24 MeV/c^2$. The statistical significance of this peak was estimated to be of $5.6 \sigma$. The mass and width of the resonance is compatible with the recently reported $\Theta^+$- baryon with positive strangeness which was predicted as an exotic pentaquark ($uudd\bar{s}$) baryon state. The total cross section for $\Theta^+$ production in pN-interactions for $X_F\ge 0$ was estimated to be $(30\div120) \mu b$ and no essential deviation from A-dependence for inelastic events $(\sim A^{0.7})$ was found.Comment: 8 pages, 7 figures, To be submitted to Yadernaya Fizika. v3-v5 - Some references added, minor typos correcte

Precision Measurement of the p(e,e ' p)pi(0) Reaction at Threshold

New results are reported from a measurement of $\pi^0$ electroproduction near threshold using the $p(e,e^{\prime} p)\pi^0$ reaction. The experiment was designed to determine precisely the energy dependence of $s-$ and $p-$wave electromagnetic multipoles as a stringent test of the predictions of Chiral Perturbation Theory (ChPT). The data were taken with an electron beam energy of 1192 MeV using a two-spectrometer setup in Hall A at Jefferson Lab. For the first time, complete coverage of the $\phi^*_{\pi}$ and $\theta^*_{\pi}$ angles in the $p \pi^0$ center-of-mass was obtained for invariant energies above threshold from 0.5 MeV up to 15 MeV. The 4-momentum transfer $Q^2$ coverage ranges from 0.05 to 0.155 (GeV/c)$^2$ in fine steps. A simple phenomenological analysis of our data shows strong disagreement with $p-$wave predictions from ChPT for $Q^2>0.07$ (GeV/c)$^2$, while the $s-$wave predictions are in reasonable agreement.Comment: 5 pages, 6 figure

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

Background Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting) is an ongoing international, prospective registry of patients with newly diagnosed non-valvular atrial fibrillation (NVAF) and at least one investigator-determined risk factor for stroke who received rivaroxaban as an initial treatment for the prevention of thromboembolic stroke. The aim of this paper is to describe the design of the RIVER registry and baseline characteristics of patients with newly diagnosed NVAF who received rivaroxaban as an initial treatment. Methods and results Between January 2014 and June 2017, RIVER investigators recruited 5072 patients at 309 centres in 17 countries. The aim was to enroll consecutive patients at sites where rivaroxaban was already routinely prescribed for stroke prevention. Each patient is being followed up prospectively for a minimum of 2-years. The registry will capture data on the rate and nature of all thromboembolic events (stroke / systemic embolism), bleeding complications, all-cause mortality and other major cardiovascular events as they occur. Data quality is assured through a combination of remote electronic monitoring and onsite monitoring (including source data verification in 10% of cases). Patients were mostly enrolled by cardiologists (n = 3776, 74.6%), by internal medicine specialists 14.2% (n = 718) and by primary care/general practice physicians 8.2% (n = 417). The mean (SD) age of the population was 69.5 (11.0) years, 44.3% were women. Mean (SD) CHADS2 score was 1.9 (1.2) and CHA2DS2-VASc scores was 3.2 (1.6). Almost all patients (98.5%) were prescribed with once daily dose of rivaroxaban, most commonly 20 mg (76.5%) and 15 mg (20.0%) as their initial treatment; 17.9% of patients received concomitant antiplatelet therapy. Most patients enrolled in RIVER met the recommended threshold for AC therapy (86.6% for 2012 ESC Guidelines, and 79.8% of patients according to 2016 ESC Guidelines). Conclusions The RIVER prospective registry will expand our knowledge of how rivaroxaban is prescribed in everyday practice and whether evidence from clinical trials can be translated to the broader cross-section of patients in the real world